S'abonner

Therapeutic depletion of myeloid lineage leukocytes in patients with generalized pustular psoriasis indicates a major role for neutrophils in the immunopathogenesis of psoriasis - 21/03/13

Doi : 10.1016/j.jaad.2012.09.037 
Shigaku Ikeda, MD a, , Hidetoshi Takahashi, MD b, Yasushi Suga, MD c, Hikaru Eto, MD d, Takafumi Etoh, MD e, Keiko Okuma, MD a, Kazuo Takahashi, MD f, Takeshi Kanbara, MD g, Mariko Seishima, MD h, Akimichi Morita, MD i, Yasutomo Imai, MD j, Takuro Kanekura, MD k
a Department of Dermatology and Allergology, Juntendo University Graduate School of Medicine, Tokyo, Japan 
b Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan 
c Department of Dermatology, Juntendo University Urayasu Hospital, Chiba, Japan 
d Department of Dermatology, St Luke's International Hospital, Tokyo, Japan 
e Department of Dermatology, Tokyo Teishin Hospital, Tokyo, Japan 
f Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan 
g Department of Dermatology, Yokohama City University Medical Center, Yokohama, Japan 
h Department of Dermatology, Gifu University Graduate School of Medicine, Gifu, Japan 
i Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan 
j Department of Dermatology, Hyogo College of Medicine, Hyogo, Japan 
k Department of Dermatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan 

Reprint requests: Shigaku Ikeda, MD, Department of Dermatology and Allergology, Juntendo University Graduate School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.

Abstract

Background

Generalized pustular psoriasis (GPP) is a chronic autoimmune disease characterized by fever, erythema, and neutrophilic pustules over large areas of the skin. GPP does not respond well to pharmacologic intervention.

Objective

We sought to assess efficacy of selectively depleting the myeloid lineage leukocytes in patients with GPP.

Methods

Fifteen patients with persistent moderate to severe GPP despite conventional therapy were included. Eligible patients had more than 10% of their skin area covered by pustules. Treatment with oral etretinate, cyclosporine, methotrexate, prednisolone, and topical prednisolone/vitamin D3 was continued if had been initiated well in advance of study entry. Five sessions of adsorptive granulocyte and monocyte apheresis (GMA) with the Adacolumn (JIMRO Co Ltd, Takasaki, Japan) were administered (1 session/wk over 5 weeks) to selectively deplete Fcγ receptor and complement receptor bearing leukocytes. Efficacy was assessed by measuring the skin areas covered by pustules at baseline and 2 weeks after the last GMA session.

Results

One patient did not complete the first GMA session. Based on the GPP severity scores relative to entry, the overall scores improved (n = 14, P = .0027), and the area of erythroderma (P = .0042), pustules (P = .0031), and edema (P = .0014) decreased. Likewise, Dermatology Life Quality Index improved (P = .0016), reflecting better daily function and quality of life. Twelve patients were judged as responders (85.7%), and 10 patients maintained the clinical response for 10 weeks after the last GMA session without any change in medication.

Limitations

This study was unblinded and without a placebo arm.

Conclusion

GMA in this clinical setting was safe and effective, suggested a major role for granulocytes/monocytes in the immunopathogenesis of GPP.

Le texte complet de cet article est disponible en PDF.

Key words : Dermatology Life Quality Index, edema, erythroderma, generalized pustular psoriasis, granulocytapheresis, granulocyte and monocyte adsorption apheresis, granulocytes and monocytes, neutrophilic pustules

Abbreviations used : ALB, CRP, GMA, GPP, IBD, IL, TNF


Plan


 Sponsored by JIMRO Co Ltd.
 Conflicts of interest: None declared.


© 2012  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 68 - N° 4

P. 609-617 - avril 2013 Retour au numéro
Article précédent Article précédent
  • Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies
  • Boni E. Elewski, Phoebe Rich, Richard Pollak, David M. Pariser, Shinichi Watanabe, Hisato Senda, Chikara Ieda, Kathleen Smith, Radhakrishnan Pillai, Tage Ramakrishna, Jason T. Olin
| Article suivant Article suivant
  • Validation of the Cutaneous Lupus Disease Area and Severity Index (CLASI) using physician- and patient-assessed health outcome measures
  • Meenakshi Jolly, Nazia Kazmi, Rachel A. Mikolaitis, Winston Sequeira, Joel A. Block

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.